Notably, the first FDA-approved biologic was dupilumab (Dupixent; Regeneron, Sanofi), and this approval took place less than 1 year ago in September 2024. Khavandi: Inhaled therapy — viewed as a ...

Dupixent becomes the first-ever targeted therapy for patients with COPD, the first biologic for the disease, and the first new treatment approach in Europe in over a decade.